Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 9,219 Shares

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $41.23, for a total value of $380,099.37. Following the sale, the insider owned 86,459 shares in the company, valued at approximately $3,564,704.57. This represents a 9.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heartflow Stock Performance

Shares of NASDAQ:HTFL opened at $45.53 on Thursday. The business has a 50-day simple moving average of $30.00 and a two-hundred day simple moving average of $28.05. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $47.23. The firm has a market cap of $3.96 billion and a price-to-earnings ratio of -24.88.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. Heartflow’s revenue for the quarter was up 47.7% compared to the same quarter last year. As a group, research analysts predict that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Institutional Trading of Heartflow

A number of institutional investors have recently modified their holdings of HTFL. XXEC Inc. acquired a new stake in Heartflow during the 2nd quarter worth about $2,524,764,000. BlackRock Inc. purchased a new stake in Heartflow in the 2nd quarter worth approximately $152,502,000. Wellington Management Group LLP purchased a new stake in Heartflow during the third quarter worth $164,263,000. Bamco Inc. NY acquired a new stake in shares of Heartflow during the 2nd quarter valued at about $94,625,000. Finally, Jupiter Topco LLC acquired a new stake in Heartflow in the second quarter valued at approximately $70,983,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HTFL shares. Morgan Stanley upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Wells Fargo & Company boosted their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Canaccord Genuity Group increased their price target on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Robert W. Baird set a $45.00 target price on shares of Heartflow in a report on Friday, August 14th. Finally, Benchmark reissued a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.43.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.